Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy

SIMPLE SUMMARY: The clinical use of immunoadjuvants is limited by transient responses and various side effects. This study investigated the multi-adjuvant approach of combining a TLR 7/8 agonist (522) and a STING agonist (DMXAA) to generate a robust anticancer immune response. Immunization with oval...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatnagar, Shubhmita, Revuri, Vishnu, Shah, Manan, Larson, Peter, Shao, Zekun, Yu, Daohai, Prabha, Swayam, Griffith, Thomas S., Ferguson, David, Panyam, Jayanth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777055/
https://www.ncbi.nlm.nih.gov/pubmed/36551577
http://dx.doi.org/10.3390/cancers14246091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777055/
https://www.ncbi.nlm.nih.gov/pubmed/36551577
http://dx.doi.org/10.3390/cancers14246091

Ejemplares similares